+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Biosimilar Monoclonal Antibodies (mAbs) Market 2020-2024- Product Image

Global Biosimilar Monoclonal Antibodies (mAbs) Market 2020-2024

  • ID: 5017679
  • Report
  • April 2020
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • MORE
Global Biosimilar Monoclonal Antibodies (mAbs) Market 2020-2024

The biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by $ 8.65 bn during 2020-2024 progressing at a CAGR of 30% during the forecast period. The reports on biosimilar monoclonal antibodies (mAbs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in prevalence of chronic diseases and increase in the number of expiring patents of blockbuster mAbs. In addition, the increase in prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The biosimilar monoclonal antibodies (mAbs) market analysis include applications segments and geographical landscapes.

The biosimilar monoclonal antibodies (mAbs) market is segmented as below:

By Application
  • Cancer
  • Non-cancer
By Geograohic Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the growing approval for biosimilar mAbs as one of the prime reason driving the biosimilar monoclonal antibodies (mAbs) market growth during the next few years.

The research presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The biosimilar monoclonal antibodies (mAbs) market covers the following areas:
  • Biosimilar monoclonal antibodies (mAbs) market sizing
  • Biosimilar monoclonal antibodies (mAbs) market forecast
  • Biosimilar monoclonal antibodies (mAbs) market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biosimilar monoclonal antibodies (mAbs) market vendors that include Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc.. Also, the biosimilar monoclonal antibodies (mAbs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The research presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Application
  • Market segments
  • Comparison by Application placement
  • Cancer - Market size and forecast 2019-2024
  • Non-cancer - Market size and forecast 2019-2024
  • Market opportunity by Application
Customer landscape
  • Overview
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
Drivers, Challenges, and Trends
  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits

1. Key Finding 1
2. Key Finding 2
3. Key Finding 3
4. Key Finding 5
5. Key Finding 6
6. Key Finding 7
7. Key Finding 8
8. Market in focus
9. Parent market
10. Market characteristics
11. Product / Service portfolio of key vendors included in the market definition
12. Market segments
13. Global - Market size and forecast 2019 - 2024 ($ billion)
14. Global market: Year-over-year growth 2019 - 2024 (%)
15. Five forces analysis 2019 & 2024
16. Bargaining power of buyers
17. Bargaining power of suppliers
18. Threat of new entrants
19. Threat of substitutes
20. Threat of rivalry
21. Market condition - Five forces 2019
22. Application placement - Market share 2019-2024 (%)
23. Comparison by Application placement
24. Cancer - Market size and forecast 2019-2024 ($ billion)
25. Cancer - Year-over-year growth 2019-2024 (%)
26. Non-cancer - Market size and forecast 2019-2024 ($ billion)
27. Non-cancer - Year-over-year growth 2019-2024 (%)
28. Market opportunity by Application
29. Customer landscape
30. Market share by geography 2019-2024 (%)
31. Geographic comparison
32. North America - Market size and forecast 2019-2024 ($ billion)
33. North America - Year-over-year growth 2019-2024 (%)
34. Europe - Market size and forecast 2019-2024 ($ billion)
35. Europe - Year-over-year growth 2019-2024 (%)
36. Asia - Market size and forecast 2019-2024 ($ billion)
37. Asia - Year-over-year growth 2019-2024 (%)
38. ROW - Market size and forecast 2019-2024 ($ billion)
39. ROW - Year-over-year growth 2019-2024 (%)
40. Key leading countries
41. Market opportunity by geography ($ billion)
42. Impact of drivers and challenges
43. Vendor landscape
44. Landscape disruption
45. Industry risks
46. Vendors covered
47. Market positioning of vendors
48. Amgen Inc. - Overview
49. Amgen Inc. - Business segments
50. Amgen Inc. - Key offerings
51. Amgen Inc. - Key customers
52. Amgen Inc. - Segment focus
53. BIOCAD - Overview
54. BIOCAD - Product and service
55. BIOCAD - Key offerings
56. BIOCAD - Key customers
57. BIOCAD - Segment focus
58. Biocon Ltd. - Overview
59. Biocon Ltd. - Business segments
60. Biocon Ltd. - Key offerings
61. Biocon Ltd. - Key customers
62. Biocon Ltd. - Segment focus
63. BioXpress Therapeutics SA - Overview
64. BioXpress Therapeutics SA - Business segments
65. BioXpress Therapeutics SA - Key offerings
66. BioXpress Therapeutics SA - Key customers
67. BioXpress Therapeutics SA - Segment focus
68. Boehringer Ingelheim International GmbH - Overview
69. Boehringer Ingelheim International GmbH - Business segments
70. Boehringer Ingelheim International GmbH - Key offerings
71. Boehringer Ingelheim International GmbH - Key customers
72. Boehringer Ingelheim International GmbH - Segment focus
73. Celltrion Inc. - Overview
74. Celltrion Inc. - Business segments
75. Celltrion Inc. - Key offerings
76. Celltrion Inc. - Key customers
77. Celltrion Inc. - Segment focus
78. Coherus BioSciences Inc. - Overview
79. Coherus BioSciences Inc. - Business segments
80. Coherus BioSciences Inc. - Key offerings
81. Coherus BioSciences Inc. - Key customers
82. Coherus BioSciences Inc. - Segment focus
83. Intas Pharmaceuticals Ltd. - Overview
84. Intas Pharmaceuticals Ltd. - Business segments
85. Intas Pharmaceuticals Ltd. - Key offerings
86. Intas Pharmaceuticals Ltd. - Key customers
87. Intas Pharmaceuticals Ltd. - Segment focus
88. Novartis AG - Overview
89. Novartis AG - Business segments
90. Novartis AG - Key offerings
91. Novartis AG - Key customers
92. Novartis AG - Segment focus
93. Pfizer Inc. - Overview
94. Pfizer Inc. - Business segments
95. Pfizer Inc. - Key offerings
96. Pfizer Inc. - Key customers
97. Pfizer Inc. - Segment focus
98. Currency conversion rates for US$
99. Research Methodology
100. Validation techniques employed for market sizing
101. Information sources
102. List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • MORE
The research team recognizes the following companies as the key players in the global biosimilar monoclonal antibodies (mAbs) market: Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing approval for biosimilar mabs."

According to the report, one of the major drivers for this market is the the increase in prevalence of chronic diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll